These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 33194628)

  • 21. Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients.
    Wang T; Liu Y; Zhou B; Hao S; Wang Z; Liang N; Liu J; Wang S
    Indian J Cancer; 2017; 54(1):215-222. PubMed ID: 29199694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Durable Response to Osimertinib in a Chinese Patient with Metastatic Lung Adenocarcinoma Harboring a Rare EGFR L858R/D761Y Compound Mutation.
    Zhu Y; Tang J; Li X; Qin T; Wei Y
    Onco Targets Ther; 2020; 13():10447-10451. PubMed ID: 33116624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
    Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
    Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
    Chabon JJ; Simmons AD; Lovejoy AF; Esfahani MS; Newman AM; Haringsma HJ; Kurtz DM; Stehr H; Scherer F; Karlovich CA; Harding TC; Durkin KA; Otterson GA; Purcell WT; Camidge DR; Goldman JW; Sequist LV; Piotrowska Z; Wakelee HA; Neal JW; Alizadeh AA; Diehn M
    Nat Commun; 2016 Jun; 7():11815. PubMed ID: 27283993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful crizotinib monotherapy in
    Yoshimura K; Inui N; Karayama M; Inoue Y; Enomoto N; Fujisawa T; Nakamura Y; Takeuchi K; Sugimura H; Suda T
    Respir Med Case Rep; 2017; 20():160-163. PubMed ID: 28271038
    [No Abstract]   [Full Text] [Related]  

  • 26.
    Ma L; Chen R; Wang F; Ma LL; Yuan MM; Chen RR; Liu J
    Ann Transl Med; 2019 May; 7(9):207. PubMed ID: 31205925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of EGFR mutation rates in lung adenocarcinoma tissue and pleural effusion samples.
    Guan Y; Wang ZJ; Wang LQ; Hua DF; Liu J
    Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
    Hicks JK; Saller J; Wang E; Boyle T; Gray JE
    Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Combined test using both cell sediment and supernatant cell-free DNA in pleural effusion shows increased sensitivity in detecting activating EGFR mutation in lung cancer patients.
    Kawahara A; Fukumitsu C; Azuma K; Taira T; Abe H; Takase Y; Murata K; Sadashima E; Hattori S; Naito Y; Akiba J
    Cytopathology; 2018 Apr; 29(2):150-155. PubMed ID: 29363841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report.
    Ma S; He Z; Fu H; Wang L; Wu X; Zhang Z; Wang Q
    Transl Lung Cancer Res; 2020 Feb; 9(1):139-143. PubMed ID: 32206560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer.
    Lee Y; Park S; Kim WS; Lee JC; Jang SJ; Choi J; Choi CM
    Thorac Cancer; 2018 Sep; 9(9):1104-1110. PubMed ID: 29989342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay.
    Wang MC; Wang CL; Chen TL; Chang JW; Lu JJ; Chang PY; Chiou CC
    Clin Chem Lab Med; 2017 Oct; 55(12):1979-1986. PubMed ID: 28787267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial.
    Fassunke J; Ihle MA; Lenze D; Lehmann A; Hummel M; Vollbrecht C; Penzel R; Volckmar AL; Stenzinger A; Endris V; Jung A; Lehmann U; Zeugner S; Baretton G; Kreipe H; Schirmacher P; Kirchner T; Dietel M; Büttner R; Merkelbach-Bruse S
    Virchows Arch; 2017 Oct; 471(4):509-520. PubMed ID: 28884371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma.
    Murano C; Igarashi A; Yamauchi K; Inoue S; Watanabe M
    EXCLI J; 2019; 18():893-898. PubMed ID: 31645848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
    Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
    Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation.
    Matsuda A; Fuchimoto Y; Wada S; Tanaka T; Takeguchi T; Mitsumune S; Takigawa Y; Miyamoto Y; Ozaki S; Iga N; Nishi H; Fujimoto N
    Case Rep Oncol; 2019; 12(3):918-921. PubMed ID: 32110209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 38. Detection of EGFR T790M in a Large Amount of Malignant Ascites Cellblock.
    Ishioka K; Sasada S; Ohgino K; Sakai T; Takahashi S; Xu C; Sugihara K; Nakamura M
    Gan To Kagaku Ryoho; 2018 Aug; 45(8):1185-1187. PubMed ID: 30158416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
    Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
    J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A marked response to icotinib in a patient with large cell neuroendocrine carcinoma harboring an EGFR mutation: A case report.
    Wang Y; Shen YH; Ma S; Zhou J
    Oncol Lett; 2015 Sep; 10(3):1575-1578. PubMed ID: 26622712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.